Terms: = Ovarian cancer AND ERBB4, MGC138404, 2066, ENSG00000178568, Q15303, p180erbB4, HER4 AND Treatment
27 results:
1. [Fertility preservation in female cancer patients.].
Vesztergom D; Székely B; Hegyi B; Masszi A; Pintér T; Csákó B; Kenessey I; Rubovszky G; Novák Z
Orv Hetil; 2023 Jul; 164(29):1134-1145. PubMed ID: 37481767
[TBL] [Abstract] [Full Text] [Related]
2. RNA-binding protein IGF2BP2 enhances circ_0000745 abundancy and promotes aggressiveness and stemness of ovarian cancer cells via the microRNA-3187-3p/erbb4/PI3K/AKT axis.
Wang S; Li Z; Zhu G; Hong L; Hu C; Wang K; Cui K; Hao C
J Ovarian Res; 2021 Nov; 14(1):154. PubMed ID: 34774079
[TBL] [Abstract] [Full Text] [Related]
3. The Anti-HER3 mAb Seribantumab Effectively Inhibits Growth of Patient-Derived and Isogenic Cell Line and Xenograft Models with Oncogenic
Odintsov I; Lui AJW; Sisso WJ; Gladstone E; Liu Z; Delasos L; Kurth RI; Sisso EM; Vojnic M; Khodos I; Mattar MS; de Stanchina E; Leland SM; Ladanyi M; Somwar R
Clin Cancer Res; 2021 Jun; 27(11):3154-3166. PubMed ID: 33824166
[TBL] [Abstract] [Full Text] [Related]
4. Combined Poziotinib with Manidipine treatment Suppresses ovarian cancer Stem-Cell Proliferation and Stemness.
Lee H; Kim JW; Lee DS; Min SH
Int J Mol Sci; 2020 Oct; 21(19):. PubMed ID: 33036254
[TBL] [Abstract] [Full Text] [Related]
5. MicroRNA-936/erbb4/Akt axis exhibits anticancer properties of gastric cancer through inhibition of cell proliferation, migration, and invasion.
Liu S; Gong Y; Xu XD; Shen H; Gao S; Bao HD; Guo SB; Yu XF; Gong J
Kaohsiung J Med Sci; 2021 Feb; 37(2):111-120. PubMed ID: 33021020
[TBL] [Abstract] [Full Text] [Related]
6. Demcizumab combined with paclitaxel for platinum-resistant ovarian, primary peritoneal, and fallopian tube cancer: The SIERRA open-label phase Ib trial.
Coleman RL; Handley KF; Burger R; Molin GZD; Stagg R; Sood AK; Moore KN
Gynecol Oncol; 2020 May; 157(2):386-391. PubMed ID: 32037195
[TBL] [Abstract] [Full Text] [Related]
7. Discrepancy in calculated and measured glomerular filtration rates in patients treated with PARP inhibitors.
Zibetti Dal Molin G; Westin SN; Msaouel P; Gomes LM; Dickens A; Coleman RL
Int J Gynecol Cancer; 2020 Jan; 30(1):89-93. PubMed ID: 31792084
[TBL] [Abstract] [Full Text] [Related]
8. Endometriosis-related infertility: ovarian endometrioma per se is not associated with presentation for infertility.
Santulli P; Lamau MC; Marcellin L; Gayet V; Marzouk P; Borghese B; Lafay Pillet MC; Chapron C
Hum Reprod; 2016 Aug; 31(8):1765-75. PubMed ID: 27130614
[TBL] [Abstract] [Full Text] [Related]
9. Dynamic modulation of phosphoprotein expression in ovarian cancer xenograft models.
Koussounadis A; Langdon SP; Um I; Kay C; Francis KE; Harrison DJ; Smith VA
BMC Cancer; 2016 Mar; 16():205. PubMed ID: 26964739
[TBL] [Abstract] [Full Text] [Related]
10. Flutamide and biomarkers in women at high risk for ovarian cancer: preclinical and clinical evidence.
Gruessner C; Gruessner A; Glaser K; AbuShahin N; Zhou Y; Laughren C; Wright H; Pinkerton S; Yi X; Stoffer J; Azodi M; Zheng W; Chambers SK
Cancer Prev Res (Phila); 2014 Sep; 7(9):896-905. PubMed ID: 24950779
[TBL] [Abstract] [Full Text] [Related]
11. Association between growth factor heregulin1α and receptors in growth of ovarian cancer cell line with high potentiality of peritoneal dissemination.
Nishiyama H; Soeda S; Watanabe T; Fujimori K
Fukushima J Med Sci; 2012; 58(1):22-32. PubMed ID: 22790889
[TBL] [Abstract] [Full Text] [Related]
12. Targeting HSP90 in ovarian cancers with multiple receptor tyrosine kinase coactivation.
Jiao Y; Ou W; Meng F; Zhou H; Wang A
Mol Cancer; 2011 Sep; 10():125. PubMed ID: 21962244
[TBL] [Abstract] [Full Text] [Related]
13. Antitumor activity of HM781-36B, a highly effective pan-HER inhibitor in erlotinib-resistant NSCLC and other EGFR-dependent cancer models.
Cha MY; Lee KO; Kim M; Song JY; Lee KH; Park J; Chae YJ; Kim YH; Suh KH; Lee GS; Park SB; Kim MS
Int J Cancer; 2012 May; 130(10):2445-54. PubMed ID: 21732342
[TBL] [Abstract] [Full Text] [Related]
14. Novel substituted quinazolines for potent EGFR tyrosine kinase inhibitors.
Cruz-López O; Conejo-García A; Núñez MC; Kimatrai M; García-Rubiño ME; Morales F; Gómez-Pérez V; Campos JM
Curr Med Chem; 2011; 18(7):943-63. PubMed ID: 21254978
[TBL] [Abstract] [Full Text] [Related]
15. Aberrant expression of DNA damage response proteins is associated with breast cancer subtype and clinical features.
Guler G; Himmetoglu C; Jimenez RE; Geyer SM; Wang WP; Costinean S; Pilarski RT; Morrison C; Suren D; Liu J; Chen J; Kamal J; Shapiro CL; Huebner K
Breast Cancer Res Treat; 2011 Sep; 129(2):421-32. PubMed ID: 21069451
[TBL] [Abstract] [Full Text] [Related]
16. Protein levels and gene expressions of the epidermal growth factor receptors, HER1, HER2, HER3 and her4 in benign and malignant ovarian tumors.
Steffensen KD; Waldstrøm M; Andersen RF; Olsen DA; Jeppesen U; Knudsen HJ; Brandslund I; Jakobsen A
Int J Oncol; 2008 Jul; 33(1):195-204. PubMed ID: 18575766
[TBL] [Abstract] [Full Text] [Related]
17. Clinical implications of the ErbB/epidermal growth factor (EGF) receptor family and its ligands in ovarian cancer.
Lafky JM; Wilken JA; Baron AT; Maihle NJ
Biochim Biophys Acta; 2008 Apr; 1785(2):232-65. PubMed ID: 18291115
[TBL] [Abstract] [Full Text] [Related]
18. ovarian granulosa cell tumors frequently express EGFR (Her-1), Her-3, and Her-4: An immunohistochemical study.
Leibl S; Bodo K; Gogg-Kammerer M; Hrzenjak A; Petru E; Winter R; Denk H; Moinfar F
Gynecol Oncol; 2006 Apr; 101(1):18-23. PubMed ID: 16330088
[TBL] [Abstract] [Full Text] [Related]
19. 2C4, a monoclonal antibody against HER2, disrupts the HER kinase signaling pathway and inhibits ovarian carcinoma cell growth.
Takai N; Jain A; Kawamata N; Popoviciu LM; Said JW; Whittaker S; Miyakawa I; Agus DB; Koeffler HP
Cancer; 2005 Dec; 104(12):2701-8. PubMed ID: 16265675
[TBL] [Abstract] [Full Text] [Related]
20. Drug development for ovarian hyper-stimulation and anti-cancer treatment: blocking of gonadotropin signaling for epiregulin and amphiregulin biosynthesis.
Freimann S; Ben-Ami I; Hirsh L; Dantes A; Halperin R; Amsterdam A
Biochem Pharmacol; 2004 Sep; 68(6):989-96. PubMed ID: 15313392
[TBL] [Abstract] [Full Text] [Related]
[Next]
